Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10444593 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL20101893 | 0.89 | ABCB11 (0.37) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL22508294 | 0.89 | ABCB11 (0.37) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL22508370 | 0.89 | ABCB11 (0.37) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444368 | 0.86 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444449 | 0.84 | ALDH1A1 (0.30) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL22508377 | 0.84 | DRD2 (0.32) | DRD2DRD3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL22508376 | 0.84 | DRD2 (0.32) | DRD2DRD3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL10444530 | 0.83 | NPC1 (0.32) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL19334813 | 0.83 | PIM1 (0.31) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4219508-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10633397-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | SHIONOGI & CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20190112315-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885 |
| US-10633397-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | C3AR1, NR4A1, HAVCR2 | ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885 |
| US-20190112315-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885 |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.